Theriva Biologics (TOVX)

• Market cap: $9.64M
• 1 day: -4.06%
• 5 days: -2.14%
• 1 month: -16.03%
• 3 months: -41.41%
• 6 months: 16.72%
• Year to date: -18.57%
• 1 year: -50.73%
• 5 years: -99.84%
• 10 years: -100%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Employees: 16